Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
516 results about "Lymph nodes size" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lymph nodes are kidney or oval shaped and range in size from a few millimeters to about 1–2 cm long. Each lymph node is surrounded by a fibrous capsule, which extends inside the lymph node to form trabeculae.
PCR method
InactiveUS7101663B2Permit useReduce errorsMicrobiological testing/measurementRecombinant DNA-technologySentinel lymph nodeCarcinoembryonic antigen
A method for balancing multiplexed PCR methods is provided. In the method, two or more sequential temporal PCR stages are used to effectively separate two or more PCR reactions in a single tube as an alternative to primer limiting to modulate the relative rate of production of a first amplicon by a first primer set and a second amplicon by a second primer set during the first and second amplification stages. Also provided are rapid RT-PCR methods that find particular use in intraoperative diagnoses and prognoses, for instance in diagnosing malignant esophageal adenocarcenoma by determining expression levels of carcinoembryonic antigen (CEA) in sentinel lymph nodes.
Owner:UNIVERSITY OF PITTSBURGH
Nanoparticles for immunotherapy
ActiveUS20080031899A1High expressionPowder deliveryCarrier-bound antigen/hapten ingredientsNanoparticleImmunotherapy
Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Nanoparticles for immunotherapy
Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Compositions and methods for the treatment of cancer
InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Systems and methods for treating, diagnosing and predicting the occurence of a medical condition
InactiveUS20070099219A1Medical simulationMicrobiological testing/measurementAbnormal tissue growthBiopsy
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including seminal vesicle involvement, surgical margin involvement, lymph node status, androgen receptor (AR) staining index of tumor, a morphometric measurement of epithelial nuclei, and at least one morphometric measurement of stroma. In another embodiment, a model that predicts clinical failure post prostatectomy is provided, wherein the model is based on features including biopsy Gleason score, lymph node involvement, prostatectomy Gleason score, a morphometric measurement of epithelial cytoplasm, a morphometric measurement of epithelial nuclei, a morphometric measurement of stroma, and intensity of androgen receptor (AR) in racemase (AMACR)-positive epithelial cells.
Owner:AUREON LAB INC +2
Automated method and system for computerized image analysis for prognosis
ActiveUS7418123B2Improved decision making regarding treatment optionsImage enhancementImage analysisTreatment optionsLesion feature
An automated method for determining prognosis based on an analysis of abnormality (lesion) features and parenchymal features obtained from medical image data of a patient. The techniques include segmentation of lesions from radiographic images, extraction of lesion features, and a merging of the features (with and without clinical information) to yield as estimate of the prognosis for the specific case. An example is given for the prognosis of breast cancer lesions using mammographic data. A computerized image analysis system for assessing prognosis combines the computerized analysis of medical images of cancerous lesions with the training-based methods of assessing prognosis of a patient, using indicators such as lymph node involvement, presence of metastatic disease, local recurrence, and / or death. It is expected that use of such a system to assess the severity of the disease will aid in improved decision-making regarding treatment options.
Owner:UNIVERSITY OF CHICAGO
Systems and methods for treating diagnosing and predicting the occurrence of a medical condition
InactiveUS20100088264A1Medical automated diagnosisKnowledge representationGleason gradeComputer generation
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all) of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR− epithelial nuclei.
Owner:AUREON LAB INC +1
Photoacoustic detection of analytes in solid tissue and detection system
InactiveUS20100285518A1Ultrasonic/sonic/infrasonic diagnosticsBioreactor/fermenter combinationsAnalyteThree-dimensional space
A preferred system for detecting an analyte in solid tissue, such as an intact lymph node, in vitro includes a laser arranged to generate a pulsed laser beam into solid tissue, which can be a fully intact lymph node. An acoustic sensor, and preferably at least three acoustic sensors are arranged in different positions to span a three dimensional space, such as in an X, Y and Z coordinate system, to detect photoacoustic signals generated within the lymph node. At least one computer receives signals from the acoustic sensor(s). The computer determines the presence or absence of, and preferably the position of analyte, from the signals and the timing of the signals. A preferred method for detecting an analyte in a lymph node in vitro includes exposing an extracted lymph node to a pulsed laser beam. A photoacoustic signal is sensed. The photoacoustic signal is analyzed to confirm the presence or absence of an analyte in the lymph node. Preferably, multiple photoacoustic signals are sensed from sensors that span a three dimensional space and the position of analyte is also determined.
Owner:UNIVERSITY OF MISSOURI
Automated Determination of Lymph Nodes in Scanned Images
Techniques include automatically detecting a lymph node in a scanned image of a body without human intervention, using one or more of three approaches. First, a subset of scanned images is determined, which belongs to one anatomical domain. A search region for lymph tissue is in a particular spatial relationship outside an anatomical object in the domain. Second, scanned images are segmented without human intervention to determine a boundary of a particular lymph node. The scanned images and outline data are received. Some of these embodiments automatically segment by determining an external marker, based on the outline data, and an internal marker, based on a geometric center of the outline data or thresholds determined automatically inside detected edges, or both, for a marker-controlled watershed algorithm. Third, based on lymph node data at a particular time, a second scanned image at a different time is segmented automatically, without human intervention.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Methods and compositions for delivery and retention of active agents to lymph nodes
InactiveUS7060689B2FlexibilityIncreasing active agent localizationGenetic material ingredientsNanomedicineMedicineActive agent
The present invention is directed to delivery and retention of active agents to targeted lymph nodes in a mammal using a ligand / anti-ligand pair. More particularly, the invention involves methods, compositions, and kits for delivery and retention of active agents to targeted lymph nodes using compositions comprising a ligand-colloid moiety and compositions comprising an anti-ligand. Active agents may be associated with one or more of the colloid, ligand, or anti-ligand. Conjugation of the ligand and anti-ligand after administration permits retention of aggregated colloid complex in targeted lymph nodes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Target tissue localization device
InactiveUS7479152B2Increase the cross-sectional areaImprove visibilitySurgical needlesDilatorsSurgeryTarget tissue
A target tissue localization device includes a tubular mesh anchor element that is secured to a placement device. In use, the localization device is passed through the patient's skin to the target tissue, creating a tissue track. The tubular mesh anchor element is located at the target tissue and expanded from a contracted to an expanded configuration. Methods for localizing a lymph node are also described. After determining the position of the lymph node, a localization device, which includes an anchor element, is localized near or within the lymph node. The anchor element is then expanded.
Owner:ARTEMIS MEDICAL
System and Method For Labeling and Identifying Lymph Nodes In Medical Images
A method for assigning a lymph node in a medical image with an anatomical name, the method including: identifying landmarks in a medical image; computing features relative to the landmarks given a location of a lymph node in the medical image; and assigning an anatomical name to the location of the lymph node by using a classifier that compares the computed features with classification rules.
Owner:SIEMENS HEALTHCARE GMBH +1
Techniques for Segmentation of Lymph Nodes, Lung Lesions and Other Solid or Part-Solid Objects
Techniques for segmentation include determining an edge of voxels in a range associated with a target object. A center voxel is determined. Target size is determined based on the center voxel. In some embodiments, edges near the center are suppressed, markers are determined based on the center, and an initial boundary is determined using a watershed transform. Some embodiments include determining multiple rays originating at the center in 3D, and determining adjacent rays for each. In some embodiments, a 2D field of amplitudes is determined on a first dimension for distance along a ray and a second dimension for successive rays in order. An initial boundary is determined based on a path of minimum cost to connect each ray. In some embodiments, active contouring is performed using a novel term to refine the initial boundary. In some embodiments, boundaries of part-solid target objects are refined using Markov models.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
InactiveCN101689220AMedical automated diagnosisSpecial data processing applicationsGleason gradeBiopsy
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all)of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR- epithelial nuclei.
Owner:AUREON LAB INC
Molecular lymphatic mapping of sentinel lymph nodes
ActiveUS20050142556A1Luminescence/biological staining preparationSugar derivativesAbnormal tissue growthRadioactive tracer
The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye / radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and / or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
Owner:JOHN WAYNE CANCER INST
Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
Owner:AUREON LAB INC +2
Immunostimulatory compositions and methods of use thereof
ActiveUS20130295129A1Enhance immune responseIncreased cellular responsePeptide/protein ingredientsImmunoglobulinsLipid formationAdjuvant
Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
Owner:MASSACHUSETTS INST OF TECH
Magnetic Probe Apparatus
A system and method for locating magnetic material. In one embodiment the system includes a magnetic probe; a power module in electrical communication with the magnetic probe to supply current to the magnetic probe; a sense module in electrical communication with the magnetic probe to receive signals from the magnetic probe; and a computer in electrical communication with the power module and the sense module. The computer generates a waveform that controls the supply of current from the power module and receives a signal from the sense module that indicates the presence of magnetic material. The magnetic probe is constructed from a material having a coefficient of thermal expansion of substantially 10−6 / ° C. or less and a Young's modulus of substantially 50 GPa or greater. In one embodiment magnetic nanoparticles are injected into a breast and the lymph nodes collecting the particles are detected with the probe and deemed sentinel nodes.
Owner:ENDOMAGNETICS LTD
Adjuvant for transcutaneous immunization
A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.
Owner:UNITED STATES OF AMERICA
Methods and compositions for diagnosis and treatment of breast cancer
InactiveUS6399328B1Control metastatic potentialOrganic active ingredientsTumor rejection antigen precursorsAbnormal tissue growthLymphatic Spread
The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. Di12 wag also present in IDC-breast cancer patient sera, and its expression level increased markedly if IDC was accompanied by lymph node or distal metastases. As IDC constitutes ~70% of breast cancers seen clinically, the level of Di12 expression is useful for diseases diagnosis predicting disease progression and monitoring a therapeutic treatment.
Owner:MUSC FOUND FOR RES DEV
Steerable sonohysterographic injection catheter for uterine cancer sentinel lymph node mapping
A steerable sonohysterographic injection catheter for identifying sentinel lymph nodes in uterine cancer patients includes a tubular shaft housing a needle extendible therefrom. The needle is preferably sized for intrauterine insertion and configured to deliver a fluid such as a contrast media to a tumor location. The catheter preferably includes a sealing device such as a selectively inflatable balloon disposed at a position along the outside of the catheter. The sealing device is configured for placement at an opening of a patient's cervix to prevent the leaking of the contrast media out of the uterus through the cervix. The distal end of the catheter is steerable so as to allow the tip of the needle to be positioned substantially near the tumor location.
Owner:WISCONSIN ALUMNI RES FOUND
Immunotherapy for immune suppressed patients
InactiveUS20060194242A1Organic active ingredientsPeptide/protein ingredientsDendritic cellCellular immunodeficiency
The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and / or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiences using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
Owner:IRX THERAPEUTICS
Immunotherapy using redirected allogeneic cells
ActiveUS20130156794A1Safe and effective adoptive transfer therapyBiocideGenetic material ingredientsAllogeneic cellDisease
A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.
Owner:YEDA RES & DEV CO LTD
Imaging probe
ActiveUS20060036157A1High sensitivityImprove quantum efficiencyDiagnostic recording/measuringSensorsRadioactive agentImaging quality
The design of a compact, handheld, solid-state and high-sensitivity imaging probe and a micro imager system is reported. These instruments can be used as a dedicated tool for detecting and locating sentinel lymph nodes and also for detecting and imaging radioactive material. The reported device will use solid state pixel detectors and custom low-noise frontend / readout integrated circuits. The detector will be designed to have excellent image quality and high spatial resolution. The imaging probes have two different embodiments, which are comprised of a pixelated detector array and a highly integrated readout system, which uses a custom multi-channel mixed signal integrated circuit. The instrument usually includes a collimator in front of the detector array so that the incident photons can be imaged. The data is transferred to an intelligent display system. A hyperspectral image can also be produced and displayed. These devices are designed to be portable for easy use.
Owner:NOVA R&D
Method of imaging lymphatic system using nanocapsule compositions
InactiveUS20050113697A1Ultrasonic/sonic/infrasonic diagnosticsEchographic/ultrasound-imaging preparationsSentinel lymph nodeRadiology
A composition is provided accompanying nonoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes.
Owner:HORIZON TECH FUNDING CO LLC
Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods
ActiveUS7470240B2Relieve painEnergy requiredUltrasonic/sonic/infrasonic diagnosticsSurgeryNervous systemFocal volume
Owner:SOFTWAVE TISSUE REGENERATION TECH LLC
Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals
InactiveUS6313373B1Restores promoter activityVectorsSugar derivativesHuman papillomavirusPromoter activity
The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus / rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.
Owner:CASE WESTERN RESERVE UNIV
In situ langerhans cell vaccine
A method for entrapping migratory antigen presenting cells (APCs) and particularly Langerhans cells (LCs,) in vivo is provided. The method entails creating an artificial gradient of APC-attracting chemotactic factor in the homing path of APCs in vivo. Also provided is a composition for entrapping APCs and particularly, migratory LCs. In addition, a method for loading APCs in situ with antigen is provided. The method comprises entrapping APCs in vivo and subsequently loading the APCs in situ with antigen. Correspondingly, a composition for loading APCs in situ is also provided. Further provided is a method for stimulating the migration of entrapped APCs to draining lymph nodes. The ability to stimulate the migration of entrapped APCs to draining lymph nodes is useful, inter alia, for regulating an immune response in a subject. In addition, an in situ APC-based vaccine is provided which does not require any time-consuming, costly ex vivo manipulations.
Owner:US SOUTHWESTERN MEDICAL CENT
Molecules that home to various selected organs or tissues
InactiveUS6933281B2NanotechCell receptors/surface-antigens/surface-determinantsAbnormal tissue growthWilms' tumor
The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.
Owner:THE BURNHAM INST
Tissue accessing and anchoring device and method
InactiveUS20050197594A1Avoid delayAvoid imprecisionSurgical needlesVaccination/ovulation diagnosticsSentinel lymph nodeRadioactive agent
The invention provides systems, methods and a node accessing and anchoring device, comprising an elongated shaft, a tissue cutting member, at least one anchoring element extending from a position at or near the distal end of the shaft; and a radiation detector. The radiation detector is effective to locate and identify sentinel lymph nodes following injection of radioactive material into a primary lesion site within a patient. The tissue cutting member, which may be activated with radio frequency energy, is effective to allow access of the elongated shaft to a sentinel lymph node. The anchoring elements are effective to anchor the device to or adjacent a sentinel lymph node accessed by the device. Anchoring elements may assume radially, longitudinally, or mixed radially and longitudinally curved or coiled configurations when deployed.
Owner:SENORX
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com